“`html
This clinical-stage biotech firm, specializing in the development of next-generation antibody complement therapeutics for severe autoimmune diseases, will conduct the event, which will include a Q&A session for registered participants. Investors can tune into the webcast via the company’s investor relations website, with a replay available shortly thereafter. This marks a pivotal moment as Dianthus Therapeutics positions itself within the competitive landscape of autoimmune disease treatments.
La società biofarmaceutica in fase clinica, specializzata nello sviluppo di terapie anticomplemento di nuova generazione per malattie autoimmuni gravi, terrà l’evento con una sessione di domande e risposte riservata ai partecipanti registrati. Gli investitori potranno seguire il webcast sul sito web dell’azienda; la registrazione sarà disponibile in seguito.
La compañía biotecnológica en fase clínica, centrada en desarrollar terapias complementarias con anticuerpos de nueva generación para enfermedades autoinmunes graves, organizará el evento e incluirá una sesión de preguntas y respuestas para los participantes registrados. Los inversores podrán acceder al webcast desde la web de la empresa y habrá una grabación disponible posteriormente.
중증 자가면역질환을 위한 차세대 항체 보체 치료제를 개발하는 임상 단계의 이 생명공학 회사는 등록 참가자를 대상으로 질의응답 세션을 포함한 행사를 진행합니다. 투자자들은 회사 웹사이트를 통해 웹캐스트에 접속할 수 있으며, 이후 다시보기 녹화도 제공됩니다.
La société biotechnologique en phase clinique, spécialisée dans le développement de thérapies complémentaires par anticorps de nouvelle génération pour les maladies auto‑immunes sévères, organisera l’événement avec une session de questions‑réponses réservée aux participants inscrits. Les investisseurs pourront accéder au webcast via le site web de la société; un replay sera disponible par la suite.
Das klinische Biotechnologie‑Unternehmen, das sich auf die Entwicklung neuartiger Antikörper‑Komplement‑Therapien für schwere Autoimmunerkrankungen spezialisiert hat, wird die Veranstaltung mit einer Fragerunde für registrierte Teilnehmer abhalten. Aktionäre können das Webcast über die Unternehmenswebsite verfolgen; eine Aufzeichnung wird im Anschluss verfügbar sein.
09/07/2025 – 06:25 PM
NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company focused on pioneering next-generation antibody complement therapeutics for severe autoimmune diseases, announced today that it will host a conference call and live audio webcast to discuss topline results from the Phase 2 MaGic trial evaluating claseprubart (DNTH103) in patients with generalized Myasthenia Gravis (gMG). The event is scheduled for tomorrow, Monday, September 8, 2025 at 8:00 a.m. EDT. The gMG market, estimated to be worth billions, represents a significant opportunity for companies developing targeted therapies.
Investor Webcast & Conference Call Information
Those interested can pre-register for the live conference call to receive dial-in details and a personal PIN for participating in the Q&A session.
A live webcast of the conference is available via the Investors and Media section of the company website. A replay of the webcast will be available following the call.
Dianthus Therapeutics: Targeting the Complement Pathway in Autoimmune Diseases
Dianthus Therapeutics is focused on developing therapies that modulate the complement pathway, a crucial component of the immune system that, when dysregulated, can drive autoimmune and inflammatory diseases. Claseprubart (DNTH103), the company’s lead asset, is designed to selectively inhibit the classical complement pathway, potentially offering a more targeted approach compared to broad-spectrum immunosuppressants.
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases. The company’s innovative approach to complement inhibition and its experienced leadership team position it as a potential disruptor in the autoimmune disease treatment landscape.
FAQ
When will Dianthus Therapeutics (DNTH) announce Phase 2 MaGic trial results for claseprubart?
Dianthus Therapeutics will announce the Phase 2 MaGic trial results during a conference call on September 8, 2025 at 8:00 a.m. EDT.
How can investors access Dianthus Therapeutics’ Phase 2 trial results conference call?
Investors can access the conference call by pre-registering to receive dial-in details and PIN, or watch the live webcast through the Investors and Media section.
What is claseprubart (DNTH103) being developed for by Dianthus Therapeutics?
Claseprubart (DNTH103) is being developed for the treatment of generalized Myasthenia Gravis (gMG), a severe autoimmune disease.
Will there be a replay available of Dianthus Therapeutics’ Phase 2 trial results presentation?
Yes, a replay of the presentation will be available in the Investors and Media section of Dianthus Therapeutics’ website after the live event.
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/8853.html
About Author
